Mattila Kalle, Raanta Pirita, Lahtela Valtteri, Pyrhönen Seppo, Koskivuo Ilkka, Vihinen Pia
Department of Oncology and Radiotherapy, University of Turku and Turku University Hospital and FICAN West Cancer Centre, Turku, Finland
Department of Oncology and Radiotherapy, University of Turku and Turku University Hospital and FICAN West Cancer Centre, Turku, Finland.
Anticancer Res. 2018 Nov;38(11):6393-6397. doi: 10.21873/anticanres.12999.
Immune checkpoint and serine/threonine-protein kinase inhibitors have become a standard of care for advanced cutaneous melanoma, but dacarbazine-based chemotherapies are occasionally used. This study assessed the long-term efficacy of chemoimmunotherapy (bleomycin, vincristine, lomustine and dacarbazine with/without subcutaneous interferon-alpha: BOLD-INF-α) as real-world data in patients with metastatic melanoma not eligible for clinical trials.
Medical data of 146 patients with stage IV melanoma who had received BOLD/BOLD-INFα regimen during 1991-2010 were analyzed.
The median overall survival was 8.9 months (95% confidence intervaI=7.5-10.4 months). The 1-year survival rate was 36%, 2-year 18%, and 5-year 13%. The 5-year survival rates in the M1a, M1b and M1c subgroups were 28%, 10% and 6%, respectively. Overall, 7% (n=11) of the patients were alive at the end of the follow-up.
Our study showed similar overall survival among patients with stage IV cutaneous melanoma treated with BOLD/BOLD-INFα as noted previously with chemotherapy.
免疫检查点抑制剂和丝氨酸/苏氨酸蛋白激酶抑制剂已成为晚期皮肤黑色素瘤的标准治疗方案，但基于达卡巴嗪的化疗偶尔仍会使用。本研究评估了化疗免疫疗法（博来霉素、长春新碱、洛莫司汀和达卡巴嗪联合/不联合皮下注射干扰素-α：BOLD-INF-α）作为不符合临床试验条件的转移性黑色素瘤患者的真实世界数据的长期疗效。
分析了1991年至2010年间接受BOLD/BOLD-INFα方案治疗的146例IV期黑色素瘤患者的医疗数据。
中位总生存期为8.9个月（95%置信区间=7.5-10.4个月）。1年生存率为36%，2年为18%，5年为13%。M1a、M1b和M1c亚组的5年生存率分别为28%、10%和6%。总体而言，7%（n=11）的患者在随访结束时仍存活。
我们的研究表明，接受BOLD/BOLD-INFα治疗的IV期皮肤黑色素瘤患者的总生存期与先前化疗的情况相似。
